Based on the 15-minute chart of Eaton Vance Tax-Managed Buy-Write Opportunities, the Relative Strength Index (RSI) has exceeded the overbought threshold, indicating that the stock price has risen too quickly and is now above the level supported by fundamental analysis. This suggests that sellers are dominating the market, and the bearish momentum is likely to persist.
Lexaria Bioscience Corp. (LEXX), a leader in developing innovative drug delivery platforms, has announced a $2 million registered direct offering of common stock. The offering is expected to close on or about April 28, 2025, and is facilitated by H.C. Wainwright & Co. [1]
The offering involves the sale of 2,000,000 shares at $1.00 per share, summing up to $2 million in gross proceeds. The proceeds will be used for working capital and general corporate purposes. Lexaria's common stock will be issued under an effective shelf registration statement on Form S-3, with accompanying final prospectus supplement and prospectus to be filed with the SEC. These documents will be available on the SEC's website once filed.
The shares have been priced at a 41% discount to the current market price, reflecting challenging conditions in capital raising and potential dilution for existing shareholders. The offering is significant given Lexaria's current market cap of approximately $24.6 million, representing a substantial portion of the company’s equity being offered at a discounted valuation.
For more information, investors are encouraged to visit Lexaria's website or contact their investor relations department.
References:
[1] https://www.gurufocus.com/news/2804554/lexaria-announces-2-million-registered-direct-offering-of-common-stock-lexx-stock-news?mobile=true
Comments
No comments yet